IXICO to present Tau PET imaging research at Human Amyloid Imaging Conference
IXICO today announces it has partnered with the Human Amyloid Imaging Conference (15-17 January 2020, Miami, USA) as a Bronze Sponsor and will be presenting scientific posters highlighting its latest methodology advances in Tau Positron Emission Tomography (PET) and Amyloid PET imaging to enhance clinical insights in Alzheimer’s therapeutic developments.
Details of the posters are as follows:
Authors: Alessandro Palombit1, Richard Manber1*, Richard Joules1, Robin Wolz1,2 1) IXICO plc, London, UK 2) Imperial College London, London, UK. *Presenting author.
Title: The impact of automatic Tau PET processing on uptake variability and power analysis in AD
Session information: Poster 38, Session 1A
Session date and time: Wednesday 15th January 9:45-10:30am
Tau protein-targeting PET based on tracer [18F]-AV-1451 (Tau-PET) offers promises in Alzheimer’s disease (AD) clinical trials but the role of PET-MR image registration on Tau-PET variability is unclear. This poster explores the variability introduced by different image registration tools for Tau-PET pre-processing.
Title: Amyloid PET variability due to variation in MRI protocol and anatomical segmentation
Session information: Poster 39, Session 1B
Session date and time: Wednesday 15th January 16:00 - 16:45pm
Variability in MRI acquisition protocol (e.g. voxel-size, contrast parameters) causes anatomical segmentation differences, introducing additional sources of cross-sectional variance in regional amyloid beta PET (Ab-PET) SUVR. This research aims to quantify the variability of Ab-PET attributable to brain segmentation differences arising from variation in MR acquisition protocol.
Dr Robin Wolz, Senior Vice President, Science & Innovation commented: “Our pioneering research in imaging analytics continues to play a pivotal role in IXICO’s work to support the advancement of effective treatments for Alzheimer’s disease. The HAI conference focuses on topics at the core of IXICO’s expertise, particularly within PET Tau imaging and we are therefore delighted to be presenting two abstracts this year while also co-sponsoring the event as a bronze partner.”
About the Human Amyloid Imaging Conference
The Human Amyloid Imaging Conference established in 2007 is organised by Keith M Johnson (Massachusetts General Hospital/Harvard Medical School), Bill Klunk (University of Pittsburgh), Chet Mathis (University of Pittsburgh) and Bill Jagust (University of California, Berkeley). The conference emphasizes ample lively discussion of core controversies such as: what does the presence of brain amyloid mean, how should it be measured, how does it change, and what does it portend? Discussions spring primarily from brief presentations by active investigators who report on unpublished, cutting-edge research in human imaging of amyloid-beta and/or other biomarkers that pertain to Alzheimer’s-related disease. HAI accepts and peer-reviews only the most recent, important work, abstract submissions. The 2019 meeting drew more than 400 attendees and showcased 155 posters from research groups spanning North America, Europe, East Asia, and Australia.
This year HAI welcomes the Alzheimer’s Association as Associate Organizer. The conference will feature three keynote presentations from Drs. Alan Evans (McGill University), Julie Schneider (Rush University) and Li-Huei Tsai (MIT).
For more information, please visit www.hai.worldeventsforum.com